Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 12, 2016Cancer DiscoveryOpen Access

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

MKMarina KonoplevaDPDaniel A. PollyeaJPJalaja Potluri

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Konopleva et al. (2016) studied this question.

synapsesocial.com/papers/69d76b7ef44a16d01ef30e2chttps://doi.org/10.1158/2159-8290.cd-16-0313
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome:2006 · 616 citations
  2. 2Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia2010 · 404 citations
  3. 3<scp>ABT</scp>‐199 selectively inhibits <scp>BCL</scp>2 but not <scp>BCL</scp>2<scp>L</scp>1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets2013 · 105 citations
  4. 4Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia2013 · 754 citations
  5. 5Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy2015 · 551 citations